Market Intelligence, Clinical Progress, and High-Purity Reagents for NADPH Oxidase Inhibitor and Chronic Granulomatous Disease Gene Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NOX2/gp91-phox drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen Complex | NOX2/gp91-phox + CYBA/p22-phox Heterodimer Protein HEK293 expressed, sequence verified, high purity (>95%), endotoxin <1EU/ug. Requires heterodimerization for stability. |
View NOX2 Products |
| Antigen (ECD-Fc) | NOX2 ECD-Fc / Mutant Protein High purity (>95%), endotoxin <1EU/ug, sequence verified. Suitable for binding assays. |
View NOX2 Products |
| Gene Delivery | NOX2 Lentivirus Premade Particles Full-length ORF with GFP reporter for stable cell line construction in K562 or HEK293T. Preserves native membrane localization and glycosylation. |
View NOX2 Products |
| Benchmark Ab | Anti-NOX2/CYBB (Research Sequence) Recombinant positive control for detection, Western blot, and co-IP. |
View NOX2 Products |
| Validator | NOX2 siRNA Set For knockdown verification in ROS functional assays. Sequence-verified specificity. |
View NOX2 Products |
| Partner Subunit | CYBA/p22-phox Recombinant Protein Essential binding partner for NOX2 maturation and membrane localization. Theoretical MW verified. |
View CYBA Products |
| Related Target | NCF1/p47-phox Cytosolic organizer subunit; critical for assembly and translocation assays. |
View NCF1 Products |
| Related Target | RAC1 GTPase regulatory subunit required for NOX2 complex activation. |
View RAC1 Products |
| Related Target | NOX1 Closest NOX isoform for selectivity counter-screening and off-target liability assessment. |
View NOX1 Products |
| Related Target | NOX4 Key parallel pathway target for ROS generation; required for selectivity testing. |
View NOX4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-subunit assembly (NOX2 requires p22phox for stability) | Co-expressed NOX2-CYBA heterodimer protein available; individual subunits for assembly studies. |
| Membrane-dependent conformation (GPCR-like complexity) | Lentivirus-based stable cell lines preserve native membrane localization, glycosylation, and complex. |
| NOX isoform selectivity (NOX1/NOX2/NOX4/NOX5/DUOX) | Complete NOX family panel proteins strictly verified by mass spec for counter-screening; lentivirus-stable cell lines for functional selectivity. |
| Cross-species CGD model evaluation (Human/Mouse) | Human and Murine NOX2 ortholog proteins available with >95% purity, sequence verified. |
| Functional validation of inhibitors | Validated siRNA controls included for specificity confirmation; ROS functional assays in stable cell lines. |
| Lack of negative controls (CGD variants) | Clinical-mimetic CYBB mutant ORF lentivirus (VAR_047264, VAR_007873, VAR_025613) available as pathway-negative reference standards. |
| Holoenzyme assembly & p47phox translocation | Co-expression systems: CYBB + CYBA full-length lentivirus; native membrane context for biophysical recruitment assays. |
| False positives in ROS assays | Validated siRNA included for CYBB-specific signal knockdown; sequence-verified reagents minimize off-target effects. |
Live NOX2/CYBB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NOX2-targeted therapeutics is bifurcating into two distinct strategies: small-molecule inhibition for inflammatory and fibrotic diseases (where NOX2-driven ROS exacerbates pathology), and gene therapy correction for Chronic Granulomatous Disease (CGD), where NOX2 loss-of-function causes life-threatening infections. As first-generation NOX inhibitors (primarily targeting NOX1/4) reach Phase II/III, the next wave of R&D is targeting the specific challenges of NOX2 selectivity—critical to avoid on-target infection risks while modulating redox signaling in non-phagocytic tissues. Major players are shifting focus from broad ROS scavengers to isoform-selective inhibition and protein-protein interaction disruptors, particularly for neurodegenerative, cardiovascular, and severe inflammatory conditions.
Functional Domains and Key Mutations
NOX2 (CYBB) contains a Ferric oxidoreductase domain (evidence: UniProt P04839) responsible for electron transfer across the membrane, and an FAD-binding FR-type domain (evidence: UniProt P04839) that binds flavin adenine dinucleotide for redox catalysis. Loss-of-function mutations in CYBB cause X-linked Chronic Granulomatous Disease (CGD). Key clinically relevant mutations include:
- VAR_047264: missense mutation associated with CGDX.
- VAR_007873 (dbSNP: rs151344455): missense mutation in CGDX.
- VAR_025613 (dbSNP: rs151344453): missense mutation in CGDX. These mutations disrupt NOX2 enzymatic activity, leading to defective ROS production and recurrent infections. Our product portfolio includes wild-type and mutant CYBB lentivirus for functional reconstitution and rescue assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Genkyotex (GKT771), GSK, Calliditas | Idiopathic Pulmonary Fibrosis, Diabetic Nephropathy, Cardiovascular, Neuroinflammation | Cell-based ROS Inhibition Assay (require intact membrane complex in stable cell lines). Selectivity vs NOX1/4 via lentivirus panel. |
| Biologic / Peptide | Various Biotechs, Academic spin-offs | Autoimmune Diseases, Inflammatory Bowel Disease, Acute Lung Injury | Conformational binding assays (need native cell lines via lentivirus); p47phox translocation assay (require full-length CYBB membrane context). |
| Gene Therapy | Sarepta Therapeutics, Orchard (GSK spin-out) | Chronic Granulomatous Disease (X-linked) | Functional reconstitution assay (NOX2 expression + ROS restoration verification using wild-type vs mutant CYBB lentivirus). |